

References

I-75

1. Datko F, D'Andrea G, Dickler M, et al. Phase 2 study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer. *Cancer Research*. 2012;72.
2. Bellmunt J, Von Der Masse H, Mead GM, et al. Randomized phase 3 study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. *Journal of Clinical Oncology*. 2012;30:1107-1113.
3. Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer: A randomised, multicentre, open-label, phase 3 trial. *Lancet Oncology*. 2014;15(4):396-405.
4. Kimura M, Usumi E, Kanematsu T, et al. Safety and continuity of second- and third-line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer. *Molecular and Clinical Oncology*. 2014;2:466-472.
5. NCCN Drugs & Biologics Compendium. Paclitaxel (Taxol®). 2014.
6. Bradley J, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer. A randomised, two-by-two factorial phase 3 study. *Lancet Oncol*. 2015;16(2):187-199.
7. Feldman D, Lim K, Patil S, et al. Paclitaxel, ifosfamide, and cisplatin efficacy for first-line treatment of patients with intermediate- or poor-risk germ cell tumors. *Journal of Clinical Oncology*. 2016.
8. Hirai F, Yamanaka T, Taguchi K, et al. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma. *Ann Oncol*. 2015;26(2):363-8.
9. Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum. *Journal of Clinical Oncology* 2013; 31:4438-4444.
10. Houédé N, Locker G, Lucas C. et al. Epicure: A European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy. *BMC Cancer*. 2016;16(1):752.
11. Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial. *Journal of Clinical Oncology*. 2015;33:2129-2135.
12. Mak R, Hunt D, Shipley W, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: A pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233. *Journal Of Clinical Oncology*. 2014;32(34):3801-9.
13. OZA. A., Cook, A., Pfisterer, J., et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer. Overall survival results of a phase 3 randomized trial. *Lancet Oncology*. 2015;16(8):928–936.

14. Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. *N Engl J Med*. 2015;372:134-141.2
15. Wanebo H, Lee J, Burtness B, et al. Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). *Ann Oncol*. 2014;(10):2036-41.
16. Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma. A double-blind, randomized phase 3 trial. *Lancet Oncol*. 2014;15D11]:1224–35.
17. National Comprehensive Cancer Network (NCCN). NCCN Drugs & Biologics Compendium. Paclitaxel (Taxol®). 2017.
18. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Bladder Cancer. 2017.
19. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Breast Cancer. 2017.
20. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Cervical Cancer. 2017.
21. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Esophageal and Esophagogastric Junction Cancers Cancer. 2017.
22. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Gastric Cancer. 2017.
23. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Head and Neck Cancers. 2017.
24. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Kidney Cancer. 2017.
25. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Melanoma. 2017.
26. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Non-Small Cell Lung Cancer. 2017.
27. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Occult Primary Cancer. 2017.
28. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Ovarian Cancer. 2017.
29. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Penile Cancer. 2017.
30. National Comprehensive Cancer Network (NCCN) *Clinical Practice Guidelines in Oncology – Soft Tissue Sarcoma – Angiosarcoma*. 2017.

31. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Testicular Cancer. .2017.
32. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Thymomas and Thymic Carcinomas. 2017.
33. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Thyroid Carcinoma - . 2017.
34. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Uterine Neoplasms . 2017.
35. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Vulvar Carcinoma, 2017.